No Prescription |
 |
 | ||
|
RIMOSLIM Acomplia |
|
| ||
No Prescription » Prescription Drugs 14 » RIMOSLIM Acomplia Appetite suppressant Anti obesity drug. significantly reducing human visceral fat (the metabolically active fat wrapped around the bodys vital organs in the abdomen Liver.A single pill has been found to stop both food and cigarette cravings enough to help people quit smoking and lose weight and could also help curb other unhealthy urges. In one study the medicine helped people who were overweight drop an average of 20 pounds and in another doubled the chances that smokers would quit. Acomplia contains the active ingredient Rimonabant. It is a selective CB1 Endocannabinoid Receptor Antagonist.Rimonabant works by blocking receptors of a substance called cannabinoid 1 which stimulates hunger and other cravings in the brain and is also present in fat tissue. Active Ingredient: Rimonabant Buy RIMOSLIM Acomplia and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About RIMOSLIM Acomplia: Product Type: Prescription Drugs 14 RIMOSLIM ( Acomplia Generic Rimonabant ) RIMOSLIM (Acomplia Generic Rimonabant) Acomplia Generic Rimonabant 20mg Acomplia Generic Rimonabant RIMOSLIM
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
